Stephen Knight is the President and Senior Managing Partner at F-Prime Capital, specializing in biopharmaceutical and medical technology investments. He leverages his dual MD and MBA degrees from Yale University to guide and build innovative healthcare companies, drawing on a career that spans research, consulting, and venture capital.
He began his career as a researcher at the prestigious AT&T Bell Laboratories before pivoting to management consulting and later to leadership roles in the pharmaceutical and venture capital industries.
Stephen Knight
President & Senior Managing Partner at F-Prime Capital (formerly Fidelity Biosciences)
Cambridge, Massachusetts, United States
Overview
Topics They Care About
Biopharma Investing
He has a long track record of investing in biopharmaceuticals, holding numerous board seats at companies like Aclaris Therapeutics, Akebia, and Adaptimmune.
Medical Technology
His professional biography and investment portfolio highlight medical technology as one of his primary areas of investment focus and expertise at F-Prime Capital.
Long-Term Company Building
He focuses on long-term venture capital support to help build sustainable and impactful healthcare companies from their early stages.
Media Appearances
Stephen has no verified media appearances
Work History
10-2003
President & Senior Managing Partner at F-Prime Capital (formerly Fidelity Biosciences)
1996 - 2003
President, COO at EPIX Pharmaceuticals
1991 - 1996
Consultant at Arthur D. Little
1985 - 1985
Researcher at AT&T Bell Laboratories
Education
1985 - 1990
MD from Yale School of Medicine
1988 - 1990
MBA from Yale School of Management
More Information
Social Presence :
Prographics :
Exp : 36
Location : Cambridge, Massachusetts, United States
Job Level : N/A
Designation : President & Senior Managing Partner at F-Prime Capital (formerly Fidelity Biosciences)
